SCHEMBL3389167

SCHEMBL3389167

NC(=O)c1cc(-c2ccccc2)cc2c(C3CCN(C(=O)c4ccccc4)CC3)n[nH]c12

nearest known ligand 0.49

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 3/20 0.49
JAK1 P23458 2/20 0.49
TYK2 P29597 2/20 0.49
JAK3 P52333 2/20 0.49
IKBKB O14920 13/20 0.46
CHUK O15111 6/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HTR2B P41595 2/20 0.44
BTK Q06187 2/20 0.44
AURKA O14965 1/20 0.44
FLT3 P36888 1/20 0.44
CSNK1E P49674 1/20 0.44
CSF1R P07333 1/20 0.43
ACHE P22303 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3392901 0.89 IKBKB (0.49) JAK2JAK1TYK2JAK3IKBKB
SCHEMBL3392944 0.84 HTT (0.47) JAK2IKBKBCHUKBTKAURKA
SCHEMBL3391393 0.83 IKBKB (0.57) IKBKBCHUKBTKAURKAFLT3
SCHEMBL27698213 0.83 IKBKB (0.48) IKBKBCHUKBTKAURKAFLT3
SCHEMBL3391461 0.83 IKBKB (0.64) IKBKBCHUKBTKAURKAFLT3
SCHEMBL3391403 0.82 IKBKB (0.69) IKBKBCHUKBTKAURKAFLT3
SCHEMBL3391202 0.82 IKBKB (0.61) IKBKBCHUKHTR2BBTKAURKA
Hydrochloric Acid SCHEMBL3395054 0.82 IKBKB (0.63) IKBKBCHUKBTKAURKAFLT3
SCHEMBL3989409 0.82 IKBKB (0.46) JAK2JAK1IKBKBCHUKBTK
SCHEMBL3392508 0.81 IKBKB (0.70) IKBKBCHUKBTKAURKAFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501780-B2 Indazole carboxamides and their use GLAXOSMITHKLINE LLC (US) 2013-08-06 US disclosed
US-8501780-B2 Indazole carboxamides and their use GLAXOSMITHKLINE LLC (US) 2013-08-06 US disclosed
US-8501780-B2 Indazole carboxamides and their use GLAXOSMITHKLINE LLC (US) 2013-08-06 US disclosed
EP-1758578-B1 NOVEL INDAZOLE CARBOXAMIDES AND THEIR USE GLAXOSMITHKLINE LLC (US) 2010-12-29 EP disclosed
EP-1758578-B1 NOVEL INDAZOLE CARBOXAMIDES AND THEIR USE GLAXOSMITHKLINE LLC (US) 2010-12-29 EP disclosed
EP-1758578-A4 NOVEL INDAZOLE CARBOXAMIDES AND THEIR USE SMITHKLINE BEECHAM CORP (US) 2009-05-27 EP disclosed
US-20070281933-A1 Novel Indazole Carboxamides And Their Use SMITHKLINE BEECHAM CORPORATION (US) 2007-12-06 US disclosed
US-20070281933-A1 Novel Indazole Carboxamides And Their Use SMITHKLINE BEECHAM CORPORATION (US) 2007-12-06 US disclosed
US-20070281933-A1 Novel Indazole Carboxamides And Their Use SMITHKLINE BEECHAM CORPORATION (US) 2007-12-06 US disclosed
EP-1758578-A2 NOVEL INDAZOLE CARBOXAMIDES AND THEIR USE Smithkline Beecham Corporation (US) 2007-03-07 EP disclosed
WO-2006002434-A2 NOVEL INDAZOLE CARBOXAMIDES AND THEIR USE SMITHKLINE BEECHAM CORPORATION (US) 2006-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281933-A1 Novel Indazole Carboxamides And Their Use IKBKG, IRAK2, NFKBIA JAK2 171/4885JAK1 65/4885TYK2 62/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.